New targeted and immunotherapies expand the treatment options for metastatic nonesmall-cell lung cancer. In this study we assessed contemporary treatment patterns and outcomes using a large electronic health record database of > 10,000 patients. Most targeted and immunotherapy use was in the second-and third-line treatment setting. Survival differences observed according to treatment type suggest that patients with actionable mutations have a survival advantage. Introduction: Multiple therapeutic options now exist for metastatic nonesmall-cell lung cancer (mNSCLC). In this study we evaluated treatment patterns and outcomes in mNSCLC patients who received first-line (1L), second-line (2L), and third-line (3L) therapy. Patients and Methods: A retrospective, observational cohort study was conducted using an electronic health record database of mNSCLC patients who received initial treatment from January 2012 through April 2016, with follow-up through June 2016. Patient characteristics and treatment patterns were characterized. Overall survival (OS) was assessed using the KaplaneMeier method. Results: We identified 10,689 1L patients. Median age was 68 years, and 5816 (54%) were male. Most patients (6337; 59%) had a performance status of 1, and 8282 (77%) had nonsquamous histology. 1L treatment was chemotherapy in 9969 (93%) patients, and targeted therapy in 685 (6%). Median OS (mOS) for all patients in 1L was 12.3 months (95% confidence interval [CI], 11.9-12.7), and 24.3 months in 1L patients receiving targeted therapy. Among patients who received 2L therapy (n ¼ 4235), 2790 (66%), 718 (17%), and 727 (17%) received chemotherapy, targeted therapy, and immunotherapy, respectively. mOS from 2L therapy was 9.6 months (95% CI, 9.1-10.1). In patients receiving 3L therapy (n ¼ 1580), 921 (58%), 355 (22%), and 304 (19%) received chemotherapy, targeted therapy, and immunotherapy, respectively. mOS from 3L therapy was 8.2 months (95% CI, 7.3-8.7). Conclusion: Targeted therapy and immunotherapy was most frequently used in the 2L and 3L setting during the study time frame. Survival differences observed according to treatment types are likely because of biologic differences, and suggest that patients with actionable mutations have a survival advantage.
Introduction
Lung cancer is the leading cause of cancer-related deaths in men as well as women in the United States. In 2017, approximately 222,500 new cases and 155,870 deaths due to lung cancer are estimated. 1 Most patients are diagnosed with metastatic nonesmall-cell lung cancer (mNSCLC), and treatment is largely palliative. The estimated 5-year survival for patients with mNSCLC from 2007 to 2013 was 4.5%. 2 Most (70%-75%) of nonesmall-cell lung cancer (NSCLC) subtypes are grouped into the nonsquamous histologic category, with the remaining grouped into the squamous category, which accounts for approximately 25% to 30%. 3 Platinum-based combination chemotherapy has been the standard of care for treatment of mNSCLC for several years, and is associated with improved survival, symptom control, and improved quality of life versus best supportive care. 4 However, treatment of mNSCLC has evolved over the past decade with the development of new therapeutic options for metastatic disease. [5] [6] [7] [8] Several biomarkers such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ), ROS1 receptor tyrosine kinase (ROS1), and programmed death cell ligand-1 (PD-L1) have emerged as predictive for therapeutic efficacy. 4 Therapies targeting these molecules were initially approved by the US Food and Drug Administration (FDA) after disease progression after at least 1 previous chemotherapy regimen. [9] [10] [11] Subsequent studies have shown improved progression-free survival (PFS) in patients with identified mutations who receive targeted therapy compared with standard chemotherapy, and EGFR and ALK inhibitors are now recommended as first-line (1L) therapy in patients with known mutations. 4, 12, 13 However, most patients do not have targetable gene abnormalities, and even among tumors that harbor these mutations, resistance to therapy eventually develops. 4 Novel targeted therapies are also now available for patients with known resistance mutations emerging after EGFR tyrosine kinase inhibitor (TKI) therapy 14 or
for patients with ALK-positive disease and progression after crizotinib. 15 In 2015, the first immunotherapy for mNSCLC was FDA-approved for use after progression during platinum-based chemotherapy and in patients with EGFR mutations or ALK rearrangements after progression during targeted therapy. 16 Multiple therapeutic options now exist for mNSCLC, including chemotherapy, targeted therapy, and immunotherapy, creating 4 To date, no studies have evaluated the best sequence of therapies and, therefore, treatment selection often depends on tumor molecular profile, performance status, and toxicities. 4 In this study we aimed to understand how these different currently available treatment options are sequenced during the course of therapy in this patient population. The objectives were: (1) to describe the demographic and clinical characteristics of patients with mNSCLC initiating treatment with chemotherapy, targeted therapy, or immunotherapy; (2) to evaluate real-world systemic treatment patterns among patients with metastatic disease according to line of therapy (LOT); and (3) to evaluate overall survival (OS) with systemic treatment for patients with mNSCLC according to LOT and treatment category.
Patients and Methods
This was a retrospective observational cohort study of patients with mNSCLC. Data were obtained via programmatic queries of The US Oncology Network iKnowMed (iKM) electronic health record (EHR) system to collect the structured, documented information available from the records. McKesson Specialty Health maintains iKM, an integrated Web-based database and oncologyspecific EHR system that captures outpatient practice encounter histories from network community oncology practices affiliated with > 1000 physicians in more than 25 practices across 400 sites of care in 19 states. Vital status data were supplemented with information obtained from the US Department of Social Security Death Index. Institutional review board approval was obtained.
The study population included patients with documented mNSCLC, defined as either stage IV at diagnosis or patients diagnosed with earlier stages who later developed evidence of metastatic disease. Patients were required to receive their initial treatment for metastatic disease between January 1, 2012, and April 30, 2016, with follow-up through June 30, 2016, or until date of last record, whichever occurred first, for a minimum potential follow-up of 2 months. The study time period was selected to capture maximum data on immunotherapy utilization after approval in 2015.
Patients were required to have 2 visits within The US Oncology Network during the study period. Patients were excluded if they were aged younger than 18 years at diagnosis, had another documented cancer before their mNSCLC, or, to avoid confounding effects of investigational therapies, if they were enrolled in a clinical trial before their initial treatment for metastatic disease.
All patients who met eligibility criteria for the treatment of mNSCLC were included in the study. Assignment of patients into treatment cohorts was on the basis of their 1L mNSCLC regimen and followed for up to 3 lines of therapy. Systemic treatments and LOT, including maintenance therapy (after 1L) during the study period, were programmatically sequenced on the basis of treatment dates and categorized as chemotherapy, targeted therapy, or immunotherapy. Regimens received by < 10% of patients were categorized as "other."
Statistical Analysis
Descriptive analyses were conducted to assess demographic, clinical, and treatment characteristics among the cohorts. Wilcoxon rank sum tests were performed for continuous variables, and c 2 tests were used for categorical variables when all cell counts were 5. The Fisher test for categorical variables was used when cell counts were < 5. Missing data were identified and reported as percentages. The KaplaneMeier method was used to estimate OS, stratified according to LOT and treatment category. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).
Results

Demographic and Baseline Characteristics
A total of 10,689 patients who met eligibility criteria and received 1L therapy during the study period were included in the analysis. a P values were comparisons between the targeted and chemotherapy groups. Wilcoxon rank sum tests for continuous variables and c 2 tests were used for categorical variables when all cell counts were 5. The Fisher test for categorical variables was used when there were cell counts < 5.
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The 1L treatment cohorts consisted predominantly of patients who initiated 1L treatment with chemotherapy (9969; 93%), 685 (6%) patients with targeted therapy, and 35 (< 1%) patients with immunotherapy ( Figure 1 ). The median age at the start of therapy was 68 years (range, 27 to 90); 8453 (79%) were white and 5816 (54%) were male. Most patients (6865; 64%) were initially diagnosed with stage IV disease. Most patients (6337; 59%) had an Eastern Cooperative Oncology Group performance status of 1, 8282 (77%) had nonsquamous histology, and 9016 (84%) were former or current smokers. Among patients who received initial targeted therapy, most were never-smokers (327; 48%) versus those who received initial chemotherapy and immunotherapy (< 10% for both; P < .0001). Tumor markers were assessed through documented structured data in the EHR. EGFR and ALK status was available in 3978 (approximately 40%) and in 3727 (35%) patients, respectively. Among those with documented results, EGFR status was positive in 524 (13%) patients; ALK was positive in 119 (3%) patients; PD-L1 status was known in 125 (< 1%) patients; and ROS1 data were not collected in this study (Table 1) .
Treatment Patterns
The most frequently used chemotherapies in the 1L setting were carboplatin with paclitaxel (3914 patients; 37%), carboplatin with pemetrexed (2231 patients; 21%), and carboplatin with paclitaxel Data are presented as n (%). Abbreviation: LOT ¼ line of therapy. a "Other" treatments individually account for < 10% of each treatment cohort.
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and bevacizumab (1395 patients; 13%). Among patients receiving targeted therapy in the 1L, erlotinib (392 patients; 57%) and crizotinib (82 patients; 12%) were most often used (Table 2 ). Sixty percent (6454 patients) of the 1L patients did not receive second-line (2L) therapy within the study period. Among the 40% of 1L patients (n ¼ 4235) who did receive 2L therapy, 2790 (66%), 718 (17%), and 727 (17%) patients received chemotherapy, targeted therapy, and immunotherapy, respectively. Pemetrexed or docetaxel monotherapy was most commonly used for 2L chemotherapy, erlotinib was most used as 2L targeted therapy, and nivolumab was most used for 2L immunotherapy. Among patients who received 1L chemotherapy and continued to 2L, most continued with 2L chemotherapy (2695; 27%). Among patients who received 1L targeted therapy and continued to 2L, most continued with 2L targeted therapy (227; 33%). Among patients who received maintenance therapy after 1L, pemetrexed (48%) was most frequently used, in 808 (48%) patients, followed by bevacizumab, used in 262 (15%) patients (data not shown).
For patients who received 2L chemotherapy (n ¼ 2790) and continued to receive third-line (3L) treatment (n ¼ 1216), most continued with 3L chemotherapy (697; 57%). For patients who received 2L targeted therapy (n ¼ 718) and went on to receive 3L treatment (n ¼ 244), more than half (127; 52%) switched to chemotherapy in the 3L, and 84 (34%) continued with targeted therapy in the 3L. Among all patients who received 3L therapy during the study period (n ¼ 1580), immunotherapy treatment with nivolumab was most frequently used (270; 17%).
Clinical Outcomes
The median follow-up time from 1L treatment initiation was 6.9 months (range, 0-54 months) for all patients in the study. KaplaneMeier survival curves for patients from the initiation of each line of treatment are shown in Figures 2-4 . Median OS (mOS) for all patients in 1L was 12.3 months (95% confidence interval [CI], 11.9-12.7). Patients who received targeted therapy in 1L were observed to have the longest survival of 24.3 months. In all patients who received 2L therapy, mOS from start of 2L was 9.6 months (95% CI, 9.1-10.1). mOS was similarly observed to be longest for patients who received targeted therapy in 2L, at 11.2 months. In all patients who received 3L therapy, the mOS from the start of 3L was 8.2 months (95% CI, 7.3-8.7). The mOS appeared longest, at 11.3 months, in patients who received 3L immunotherapy. Among the subset of patients who received only 1L therapy of any type (n ¼ 6396), mOS was 7.2 months (95% CI, 6.9-7.5). The mOS among patients who received only 1L and 2L therapy of any type (n ¼ 2623) was 14.7 months (95% CI, 13.8-15.4). The mOS among patients who received 1L, 2L, and 3L therapy of any type (n ¼ 1568) was 23.0 months (95% CI, 21.8-24.8; Figure 5 ).
Discussion
A large EHR database population was used to examine real-world patient characteristics, treatment patterns, and clinical outcomes involving the use of chemotherapy, newer targeted therapies, and immunotherapies for mNSCLC. Use of EHR database information provided insight into initial treatment utilization in real-world clinical practice, including at a time when biomarker testing was not universal and the effect of mutational status was not as well known.
In this study, most of the patient population received initial platinum-based chemotherapy in the 1L setting (7540; 71%), because this has been the standard of care for several years and many of the new drugs that gained FDA approval during the study period required disease progression after platinum-based therapy. 4 These results are similar to other smaller published real-world utilization studies of similar time frames reporting a range of 61% to 85% utilization of 1L platinum-containing chemotherapy, depending on EGFR or ALK status. 17, 18 Utilization rate of 1L chemotherapy is lower when there is a known actionable mutation. More variability in treatment modality was observed in this study in the 2L or 3L setting, with higher rates of use of targeted therapy or immunotherapy in 2L or 3L compared with 1L. In this study, the most frequently used regimens in the 2L setting were pemetrexed (696; 16%), docetaxel (694; 16%), nivolumab (674; 16%), and erlotinib (458; 11%). The same drugs at slightly different rates were most frequently used in the 3L setting: nivolumab (270; 17%), docetaxel (227; 14%), erlotinib (224; 14%), and pemetrexed (158; 10%). 
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This is also consistent with the aforementioned real-world study reporting 14% use of docetaxel in the 2L setting, and a diverse range of other 2L therapies with > 90 different regimens. 17 It is important to note that the use of targeted therapies in a nontargeted population was an established treatment option during the study time period. On the basis of the study time frame, most patients who received targeted therapy as 1L did so as a result of known gene mutations. However, the large proportion of patients who received targeted therapy in the 2L might have included patients who did not have mutation testing results known by the time chemotherapy was initiated (eg, poor tissue sample or symptomatic patients necessitating initial chemotherapy treatment) and therefore received targeted therapy in 2L. In addition, some patients might still have received EGFR TKIs as palliative therapy regardless of EGFR status, if their status was unknown or if the patient had poor performance status. Patients who received 3L EGFR TKIs were likely given this therapy on the basis of factors other than mutation status. With increasing data showing the predictive value of biomarkers (eg, EGFR mutational status), changes in the labels for EGFR TKIs have occurred over time. In 2004, erlotinib was first FDA-approved for mNSCLC regardless of EGFR status. 9 Now, it is indicated only for patients with known EGFR mutations. 5 In 2013, approval was modified to include the 1L treatment of patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. 19 Effective October 2016, the labeling change also applied to patients receiving maintenance or 2L or greater treatment, requiring patients to have a known EGFRsensitizing mutation for use. 5, 20 In 2015, the pathologic classification of lung cancer mandated immunohistochemistry and molecular analysis in routine clinical practice.
4,21
Phase 3 studies such as the Iressa Pan-Asia Study (IPASS) and the European Randomised Trial of Tarceva versus Chemotherapy (EURTAC) showed that patients with EGFR mutations receiving 1L chemotherapy followed by an EGFR TKI, or 1L EGFR TKI followed by chemotherapy, had the same outcome in terms of OS, but the benefits in tolerability and PFS were much higher with 1L targeted therapies. 12, 22 In IPASS as well as EURTAC, mOS did not differ significantly between the gefitinib arm and erlotinib arm Eric Nadler et al
Clinical Lung Cancer July 2018 -367 versus the chemotherapy arms. 12, 20 In IPASS, mOS with 1L targeted therapy with gefitinib was 18.8 months versus 17.4 months with 1L chemotherapy (P ¼ .109). 22 In the EURTAC study, mOS was 19.3 months in the 1L erlotinib group compared with 19.5 months in the standard chemotherapy group (P ¼ .87).
12
A large consortium study assessed the frequency and outcomes associated with various oncogenic drivers in patients with stage IV or recurrent adenocarcinoma of the lung, and at least 1 gene mutation was found in 64% of patients. Among the actionable mutations with targeted therapies, an EGFR-sensitizing mutation was found in 17% of patients, and ALK rearrangement in 8%. It was shown that patients with oncogenic drivers treated with targeted therapies had improved survival over those who did not receive targeted therapies, hence potentially treated with chemotherapy, with a median survival of 3.5 years versus 2.4 years (hazard ratio, 0.69; 95% CI, 0.53-0.9; P ¼ .006). 23 In our real-world study, we observed improved OS of 24.3 months in patients who received 1L targeted therapy versus 11.7 months for 1L chemotherapy. Our data provide additional evidence that patients with actionable mutations derive greater survival benefit from targeted therapies. In our study, 524 (5%) and 119 (1%) patients who received treatment were known to be EGFR mutation positive and ALK rearrangement positive, whereas the status was unknown for 63% of EGFR mutation and 65% of ALK rearrangement. One cannot be certain if the patients were never tested, or if the results were not readily available.
Because growing evidence from studies show improved outcomes in those who receive treatment for known actionable targets, this further reinforces the importance of testing. It should be noted that survival estimates in this study reflect those of metastatic patients diagnosed and treated, because eligibility included all patients who initiated 1L treatment, and did not include patients who did not receive therapy. One study reported that only 24% of NSCLC patients receive 1L chemotherapy, and only 31% of these patients receive 2L therapy. 24 So OS estimates might be lower if untreated patients were included in this analysis. Overall survival estimates from the present study were consistent with the ranges reported in the immunotherapy registrational clinical trials. 16, 25 Among patients who initiated immunotherapy in the 
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2L and 3L setting in this study, the mOS was 9.7 and 11.3 months, respectively. In comparison, the Checkmate-057 and Keynote-010 studies that evaluated the use of nivolumab or pembrolizumab versus docetaxel for 2L treatment of mNSCLC reported significantly improved mOS of 12.2 and 12.7 months with nivolumab and pembrolizumab, versus 9.4 and 8.5 months with docetaxel, respectively. 16, 25 3L EGFR TKIs in this real-world study were likely not given to patients on the basis of mutational status, and in these patients the OS was similar to chemotherapy and of modest benefit with either therapy.
Comparisons of patient outcomes among treatment groups should be interpreted with caution, because it is known that the groups are biologically different considering the variable rate of known biomarker status among the population during the study time period. The treatment landscape for use of targeted therapies in NSCLC has evolved over the years, yet there continues to be unmet need in patients without known targets.
The increases in mOS reported among patients who received 1L only, 1L and 2L only, and up to 3L also illustrate the increased likelihood of response to subsequent lines of therapy among patients who respond to 1L compared with those who do not. These observations are likely also explained by differences in the underlying biology of disease in these patients, which is not well understood.
The strength of this study lies in the large, multisite population of mNSCLC patients who were treated with multiple lines of therapy in the community oncology setting. Data collected from the EHR database represent actual treatment information documented as part of routine clinical care, and therefore show real-world clinical treatment patterns and outcomes, not only those of patients selected as part of clinical trials.
Limitations of this study include the retrospective nature of the evaluation, short follow-up time in more recently selected patients, and potential for documentation bias if there were omissions or errors in the EHR database. Missing data cannot confirm the absence of a condition or value in patients' medical histories, only that it was not documented. Oral therapies are prescribed through iKM, but the fulfillment of those prescriptions is not observable; therefore, an intent to treat approach was used for oral therapies. This study was limited to clinics that are part of The US Oncology Network and might not be generalizable to practices outside of the network.
Conclusion
These data show timely translation of randomized trial data and integration of novel therapies for mNSCLC in the community setting. Use of targeted therapy was frequently observed in the 1L setting for mutation-positive patients, and survival with immunotherapy in the 2L was similar to that reported in the registrational trials. OS for patients who received multiple lines of therapy was better than in patients who did not. Differences in survival according to treatment types are likely because of biologic differences.
Clinical Practice Points
Identification of biomarkers in mNSCLC such as EGFR mutations and ALK rearrangements helps select patients who will derive maximal benefit from TKIs directed against these targets.
In 2015, the first immunotherapy for mNSCLC was FDA-approved for use in patients after progression during platinum-based chemotherapy and after targeted therapy in patients with known mutations. Recent and ongoing studies are evaluating different sequencing options for these treatments. Effective October 2016, the indication for using EGFR TKIs changed to require patients treated in all lines of therapy for metastatic disease to have a known EGFR-sensitizing mutation (EGFR exon 19 deletions or exon 21 L858R substitution mutations detected using an FDA-approved test). During the study period, platinum-based chemotherapy was the most frequently used treatment in the 1L setting, followed by targeted therapy or immunotherapy in 2L or 3L. These data show that patients with actionable mutations can derive greater survival benefit from targeted therapies compared with chemotherapy, and provide evidence that incorporation of immunotherapy can improve OS more than chemotherapy.
